Idiopathic pulmonary fibrosis (IPF) is the most common of the idiopathic interstitial pneumonias 1 and accounts for about 20 % of all interstitial lung diseases (ILD). 2 IPF should be considered in all adult patients with unexplained chronic exertional dyspnea, 3 though it is rare in patients less than 50 years of age. 
Presence of ground glass does not exclude UIP so long as there is a greater degree of reticulation. 8 Emphysematous changes may complicate HRCT interpretation and has been shown to result in mistaking UIP for chronic pulmonary emphysema with fibrosis (CPEF) as well as nonspecific interstitial pneumonia (NSIP). 9 Appearance of the UIP distribution may be asymmetrical in up to 25 % of cases. 10 The most common differential diagnoses for IPF are cHP, CT-ILD, and pneumoconiosis with particular emphasis on asbestosis. 3 Concomitant features such as centrilobular nodules, air trapping, and relative sparing of the bases may be suggestive of hypersensitivity pneumonitis; pleural plaques suggest asbestosis; and septal or bronchovascular nodules may be present in sarcoidosis. 11 CT-ILD should be considered in the presence of pleural effusion and/or pleural thickening, as well as esophageal dilation.
11
Differentiating cHP from UIP/IPF may be difficult, as many times the offending antigen may not be discoverable. 12 
Failed Therapies
Potentially harmful medications in the treatment of IPF include warfarin 17 and the combination of prednisone, azathioprine, and N-acetylcysteine. 18 Sildenafil has failed to show improvement in forced vital capacity (FVC), dyspnea score, and mortality. 19, 20 A signal of harm was displayed with the use of selective endothelin receptor antagonist (ERA), ambrisentan, even in the presence of pulmonary hypertension (PH). 21 In general, nonselective ERAs (bosentan, macitentan) should not be used in IPF, though it remains unclear if there may be a beneficial role in patients with PH secondary to IPF.
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Current Principles of Management
Gastroesophageal reflux (GER) is seen in up to 90 % of patients with IPF, but often clinically silent. [25] [26] [27] Antiacid treatments may decrease the risk of microaspiration-associated lung injury and have been shown to decrease the rate of FVC decline. This year, a sensitivity analysis of ASCEND demonstrated that at week 52, the proportion of patients with a 10 % decline in FVC or death was decreased by 47.8 %, and the proportion of patients with no decline was increased by 132.5 %. 35 The most common adverse effects of pirfenidone included cough, nausea, headache, diarrhea, upper respiratory infection, fatigue, and rash, leading to discontinuation of the drug in 14.4 % of patients in ASCEND compared to a 10.8 % placebo discontinuation rate.
Elevation of liver enzymes >3 times upper limit of normal occurred in <3 % of patients. 34 Later, 178 patients who had previously been randomized to the control group in CAPACITY were included in an open-label extension, RECAP. In this study, the mean decline in FVC at week 60 was −5.9 %, an even better outcome than in the CAPACITY treatment group (−7.0 %). . 42 Both were 52-week protocols where neither found a mortality benefit nor reduction in acute IPF exacerbation rate. However, patients on nintedanib had an average 52 % reduction in FVC loss, representing about 125 ml spared annually. 42 The most common adverse event was diarrhea (>60 %), followed by nausea. Elevation of liver function tests occurred in about 5 % of patients on nintedanib.
During the INPULSIS series, 10 patients on nintedanib suffered myocardial infarctions, compared with two patients receiving placebo. Worth noting is that some patients enrolled in INPULSIS were included with HRCT interpreted as "probable UIP" and not confirmed with biopsy. It is unclear whether this may suggest the benefit of nintedanib in non-UIP ILD or rather an underestimation of its effect in true UIP due to inappropriate inclusion criteria.
Comparison of the available data shows similar reductions in FVC decline of 45.1 % with pirfenidone, and 52.2 % with nintedanib. With time, nintedanib may show an improvement in mortality comparable to that of pirfenidone. The practical interpretation and application of the differences in data between the two drugs is unclear in that the groups of patients studied were not the same. 
Conclusion
Despite the recent addition of two medications for IPF that slow lung function decline, IPF remains a deadly disease. Avoidance of smoking should be strongly advised, and poignant management of comorbidities such as GER should be undertaken. We have entered a new era in the management of IPF, but curing the disease remains a current goal.■
